Please note our Product Finder does not contain our complete product portfolio. Should you wish for further information on a specific product, please contact us.
Contact customer care

Boulogne-Billancourt (France), March 11, 2021 – Delpharm Evreux, European leading contract development and manufacturing organization (CDMO) with a major expertise in Oral Solid Dose and Softgel Capsules, in collaboration with Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, has successfully scaled and qualified a new softgel capsule with a plant-based shell. 

Based on Roquette’s LYCAGEL™ pea starch softgel technology, this vegetarian softgel is composed of hydroxypropyl pea starch, carrageenan and other functional ingredients. It meets the requirements for both nutraceutical supplement and pharmaceutical softgel products.

“Delpharm is proud to have brought its expertise in this main project with Roquette to lead to the production of a new vegetarian soft gel capsule,” said Stéphane Latouille, Head of soft gel capsule operational support at Delpharm.

The industrial batches performed on Delpharm Evreux equipment have demonstrated the capability to produce such softgel capsules with a high robustness within the expected specifications similar to animal gelatin ingredients.

The machine speed to manufacture the capsules is similar to the current process demonstrated for many years without any major mechanical and process modifications.

“Working with a leading CDMO like Delpharm as an early adopter of LYCAGEL™ helped prove the technology at scale,” said Brian Koblinski, Global Market Manager at Roquette. “Delpharm was quick to see the value of this plant-based softgel solution for its nutraceutical and pharmaceutical customer base. This development reflects again our continued commitment to our customers so that they remain at the forefront of innovation. We are very pleased to contribute to meet the fast-growing consumer demand for plant-based products with our key partners such as Delpharm.”

After this success and with this new expertise, Delpharm Evreux can now propose to its customers a wide range of softgel capsules. This competitive advantage will be without any doubt one of the major strategic initiatives in the coming months for Delpharm.

For more information on LYCAGEL™, please visit this page.

About Delpharm Evreux
Acquired by Delpharm in 2002, Delpharm Evreux is one of the group's 17 production sites and stands out for its huge expertise in Oral Solid Dose and Softgel Capsules. Delpharm is a worldwide leader in contract manufacturing and development of medicines for pharmaceutical companies. The company offers products such as Rx and generics; medical devices, OTC and veterinary products. It provides services such as manufacturing, packaging, API sourcing, regulatory services, life cycle management. Delpharm operates 17 manufacturing plants (12 in France, 2 in Italy, 1 in Belgium, 1 in Canada and 1 in The Netherlands) providing most of the dosage forms available on the market: tablets, injectable vials and ampoules, freeze dry, suspensions, solutions, ointments and softgels, etc. Delpharm generates €800m in turnover and is wholly-owned by its management.
More on

About Roquette
Learn morea about us

Media contacts


Communication and Marketing Manager 
Mathilde Cahu 
[email protected] 


Corporate Communications 
Carole Petitjean 
[email protected] 

Global Pharmaceutical Communications 
Lena Stinsa 
[email protected]